Menu Search
Equities

CorMedix Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
19KA:DUS

CorMedix Inc

Actions
  • Price (EUR)6.25
  • Today's Change0.05 / 0.81%
  • Shares traded150.00
  • 1 Year change-37.50%
  • Beta1.3043
Data delayed at least 15 minutes, as of Feb 06 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

  • Revenue in USD (TTM)214.30m
  • Net income in USD162.50m
  • Incorporated2006
  • Employees64.00
  • Location
    CorMedix Inc300 Connell Drive, Suite 4200BERKELEY HEIGHTS 07922United StatesUSA
  • Phone+1 (908) 517-9500
  • Fax+1 (302) 636-5454
  • Websitehttps://cormedix.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CRMD:NMQ since
announced		Transaction
value
Melinta Therapeutics LLCDeal completed07 Aug 202507 Aug 2025Deal completed-35.65%300.00m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.